Tag: rimegepant

  • Gepants for Migraine Prevention: Atogepant and Rimegepant

    Gepants for Migraine Prevention: Atogepant and Rimegepant

    In recent years, gepants have become one of the most important advances in migraine treatment. While originally developed for acute migraine relief, certain gepants are now also approved for migraine prevention. Unlike older oral preventives—many of which were borrowed from epilepsy, depression, or blood pressure treatment—gepants were designed specifically around migraine biology.

    The two oral gepants approved for migraine prevention are atogepant and rimegepant. For many patients, they offer an effective and well-tolerated preventive option without the drawbacks of traditional therapies.

    How Gepants Work in Migraine

    Migraine is driven in large part by the activity of calcitonin gene-related peptide (CGRP). During a migraine attack, CGRP is released from trigeminal nerve endings, leading to several downstream effects.

    CGRP:

    • Dilates blood vessels in the brain
    • Increases inflammation around pain-sensitive nerves
    • Amplifies pain signaling pathways

    Gepants work by blocking the CGRP receptor, preventing CGRP from activating these migraine pathways. By interrupting this process early, gepants reduce the brain’s sensitivity to migraine triggers and help prevent attacks before they start.

    Extensive research on CGRP’s role in migraine has been published in journals such as The New England Journal of Medicine and Cephalalgia.

    Atogepant (Qulipta) for Migraine Prevention

    Atogepant is the first gepant approved specifically for preventive treatment of migraine.

    Evidence for Effectiveness

    Large randomized clinical trials, including ADVANCE and PROGRESS, demonstrated that atogepant is effective in both episodic and chronic migraine.

    Key findings include:

    • An average reduction of 4–7 monthly migraine days
    • Approximately 50–60% of patients achieved at least a 50% reduction in migraine frequency
    • Benefits were sustained over long-term follow-up, with continued improvement over months

    Results from these trials were published in leading journals such as The Lancet and JAMA.

    Dosing

    • Taken once daily by mouth
    • Available doses range from 10 mg to 60 mg, depending on patient profile and tolerability

    The simplicity of once-daily dosing makes atogepant easy to integrate into daily routines.

    Side Effects

    Atogepant is generally well tolerated. The most commonly reported side effects are:

    • Constipation
    • Nausea
    • Fatigue

    Compared with older oral preventives, systemic side effects are usually mild.

    Rimegepant (Nurtec ODT) for Migraine Prevention

    Rimegepant is unique among migraine medications because it is approved for both acute and preventive treatment.

    Evidence for Effectiveness

    In preventive trials, patients taking rimegepant every other day experienced:

    • A reduction of 4–5 monthly migraine days compared with placebo
    • Sustained benefit over one year of treatment
    • Improved quality-of-life scores and reduced need for acute medications

    These findings have been published in Headache: The Journal of Head and Face Pain and Neurology.

    Dosing

    • 75 mg orally disintegrating tablet (ODT)
    • Taken every other day for prevention
    • Dissolves on the tongue without water, offering convenience and discretion

    Side Effects

    • Nausea is the most commonly reported side effect
    • Overall tolerability is excellent
    • Rare hypersensitivity reactions have been reported

    Gepants vs CGRP Monoclonal Antibodies

    Both gepants and CGRP monoclonal antibodies target the CGRP pathway, but they differ in how they are used.

    • Gepants (atogepant, rimegepant)
      • Oral dosing (daily or every other day)
      • Shorter-acting and fully reversible
      • Mild gastrointestinal side effects in some patients
    • CGRP monoclonal antibodies
      • Injectable (monthly or quarterly)
      • Long-acting and convenient for adherence
      • Injection-site reactions or constipation in some patients

    Both approaches are highly effective. The choice often depends on patient preference, insurance coverage, comorbid conditions, and prior treatment response.

    Who Should Consider Gepants for Prevention?

    Preventive gepants may be a good option for:

    • Patients with frequent migraine attacks not well controlled on older preventives
    • Those who cannot tolerate topiramate, beta-blockers, or antidepressants
    • Patients who prefer oral therapy over injections
    • People with migraine and cardiovascular disease, where triptans or some older preventives may be limited

    Access and Coverage in Canada

    Access to gepants continues to evolve in Canada.

    Currently:

    • Atogepant is approved for migraine prevention, with coverage depending on private insurance or special authorization
    • Rimegepant is approved for both acute and preventive use, though not all provincial drug plans cover it yet
    • Out-of-pocket costs can be high without insurance

    Manufacturer patient support programs and private insurance plans may help reduce financial barriers.

    Practical Tips for Patients

    • Take consistently: Preventive gepants work best when taken on schedule
    • Track migraine days to assess benefit and support coverage approvals
    • Be patient: Improvement often begins within 4–8 weeks, with full benefit by about 3 months
    • Report side effects, especially persistent constipation or fatigue
    • Ask about coverage support, including manufacturer programs

    Lifestyle strategies such as regular sleep, hydration, and stress management further improve outcomes.

    Take-Home Message

    Atogepant and rimegepant represent a major step forward in migraine prevention. By targeting the CGRP pathway with convenient oral dosing, they provide effective and well-tolerated alternatives to traditional preventive medications.

    For patients seeking an oral option without the cognitive, weight, or cardiovascular side effects of older therapies, gepants offer new hope for long-term migraine control.

  • Gepants for Acute Migraine: Rimegepant and Ubrogepant

    Gepants for Acute Migraine: Rimegepant and Ubrogepant

    For many years, acute migraine treatment relied heavily on triptans and NSAIDs. While these medications help countless patients, they aren’t right for everyone. Some people cannot use triptans because of cardiovascular concerns, while others struggle with stomach irritation or inadequate relief from NSAIDs.

    That’s where gepants for acute migraine come in. Gepants—specifically rimegepant and ubrogepant—offer a modern, highly targeted option that works directly on the CGRP pathway, a major driver of migraine attacks. Because they don’t constrict blood vessels, gepants provide a safer alternative for patients with cardiovascular risk factors, while still delivering meaningful, long-lasting relief.

    What Are Gepants?

    Gepants are a newer class of oral medications designed to block calcitonin gene-related peptide (CGRP), a key molecule involved in migraine pain, inflammation, and sensitivity. During a migraine, CGRP levels rise and promote:

    • Blood vessel dilation
    • Inflammation around nerve endings
    • Enhanced pain signaling in the brain

    By blocking CGRP receptors, gepants interrupt the migraine process without affecting blood vessels. This makes them fundamentally different from triptans, which tighten blood vessels and therefore cannot be used in people with certain heart or stroke risks.

    The two gepants currently approved for acute migraine treatment are:

    • Rimegepant (Nurtec ODT)
    • Ubrogepant (Ubrelvy)

    Rimegepant is also approved for preventive use in some regions, making it the first dual-purpose CGRP medication.

    How Do Gepants Work?

    Both rimegepant and ubrogepant bind to CGRP receptors and block them from activating migraine-related pain pathways. This mechanism helps reduce:

    • Head pain
    • Nausea
    • Light and sound sensitivity
    • Overall migraine severity

    Unlike many other acute treatments, gepants do not cause chest tightness, vascular changes, or sedation. They target the source of the attack without affecting heart or blood vessel function.

    Effectiveness of Gepants

    Clinical studies—including those published in Cephalalgia and Neurology Journal show strong, consistent benefits for rimegepant and ubrogepant:

    • Pain freedom at 2 hours: ~20% of patients become completely pain-free, compared with ~10% using placebo
    • Relief of the most bothersome symptom: ~35–40% notice improvement in symptoms such as nausea or light sensitivity
    • Sustained relief for up to 48 hours without needing additional doses

    While gepants may not always act as quickly as some triptans, their longer duration and excellent tolerability make them a valuable option for many patients.

    How to Take Gepants

    Rimegepant (Nurtec ODT)

    • Dose: 75 mg, placed on the tongue
    • Dissolves without water, helpful during nausea
    • One dose per 24 hours

    Ubrogepant (Ubrelvy)

    • Dose: 50 mg or 100 mg tablet
    • May take a second dose after 2 hours if needed
    • Maximum: 200 mg in 24 hours

    Both medications work best when taken early in the migraine attack, but unlike some other treatments, they can still be effective later if the early window is missed.

    Side Effects and Safety

    Gepants are generally very well tolerated. The most common side effects are mild and short-lived:

    • Nausea
    • Drowsiness or fatigue
    • Dry mouth

    Crucially, gepants do not cause:

    • Chest tightness
    • Vasoconstriction
    • Medication overuse headache (MOH), based on current evidence

    Because gepants are metabolized in the liver, patients with significant liver disease or those using strong CYP3A4 inhibitors (certain antifungals, some antibiotics, and others) may need dosage adjustments or may need to avoid gepants altogether.

    Who Benefits Most from Gepants?

    Gepants for acute migraine are especially useful for:

    • Patients who cannot take triptans because of heart disease, stroke history, or vascular risk factors
    • Patients who don’t respond well to triptans, or who get side effects
    • Patients who can’t tolerate NSAIDs due to gastrointestinal issues
    • Those looking for longer-lasting relief with a low side-effect burden

    They’re also helpful for patients who experience delayed migraines or who need a gentle but effective alternative.

    Gepants vs. Triptans

    FeatureTriptansGepants (Rimegepant, Ubrogepant)
    MechanismSerotonin receptor agonistsCGRP receptor antagonists
    Vascular effectsConstrict blood vesselsNo constriction
    Onset of actionOften fasterEffective, sometimes slower
    Use in heart diseaseContraindicatedGenerally safe
    Medication overuse headachePossible with frequent useNot shown to cause MOH

    Gepants don’t replace triptans entirely—they offer an alternative for patients who cannot or prefer not to use them.

    Access in Canada

    Access to gepants in Canada is evolving:

    • Rimegepant is approved for acute treatment and preventive treatment.
    • Ubrogepant is approved for acute treatment.
    • Coverage varies by province and insurance plan.
    • Some patients require special authorization or rely on private insurance.
    • Cost may be a barrier without coverage.

    Patients should check with their insurer or provincial drug program to explore affordability and eligibility.

    Practical Tips for Patients

    • Use early, but don’t worry if you miss the first hour—gepants still have benefit later.
    • Don’t stress over medication overuse headache: Gepants have not been shown to cause MOH.
    • Disclose all medications: Important to avoid liver-related interactions.
    • Track your results: Note pain relief, symptom changes, and duration.
    • Investigate insurance coverage: Some plans require special approval.

    Keeping a migraine diary can help identify patterns and help clinicians optimize your treatment plan.

    Take-Home Message

    Gepants like rimegepant and ubrogepant represent a major advancement in acute migraine care. By blocking the CGRP pathway, they provide targeted relief without the cardiovascular risks associated with triptans—and without the concerns of medication overuse headache. Although access and cost can be limiting factors, these medications offer valuable options for patients seeking safe, effective, and well-tolerated acute treatment.